[1] Thygesen K, Alpert J S, White H D. Universal definition of myocardial infarction[J]. Journal of the American College of Cardiology, 2007, 50(22): 2173-2195.
[2] Lawrie D M, Higgins M R, Godman M J, et al. Ventricular fibrillation complicating acute myocardial infarction[J]. The Lancet, 1968, 292(7567): 523-528.
[3] DANSON E J F, PATERSON D J. Reactive oxygen species and autonomic regulation of cardiac excitability[J]. Journal of Cardiovascular Electrophysiology, 2006, 17: S104-S112.
[4] Talman W T, Kelkar P. Neural control of the heart: central and peripheral[J]. Neurologic Clinics, 1993, 11(2): 239-256.
[5] Lampert R, Jain D, Burg M M, et al. Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators[J]. Circulation, 2000, 101(2): 158-164.
[6] Davis A M, Natelson B H. Brain-heart interactions. The neurocardiology of arrhythmia and sudden cardiac death[J]. Texas Heart Institute Journal, 1993, 20(3): 158.
[7] Sawchenko P E, Swanson L W. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat[J]. Journal of Comparative Neurology, 1982, 205(3): 260-272.
[8] Badoer E. Hypothalamic paraventricular nucleus and cardiovascular regulation[J]. Clinical and Experimental Pharmacology & Physiology, 2001, 28(1-2): 95-99.
[9] Kang Y M, He R L, Yang L M, et al. Brain tumour necrosis factor-α modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure[J]. Cardiovascular Research, 2009, 83(4): 737-746.
[10] Qi J, Zhao X F, Yu X J, et al. Targeting interleukin-1 beta to suppress sympathoexcitation in hypothalamic paraventricular nucleus in Dahl salt-sensitive hypertensive rats[J]. Cardiovascular Toxicology, 2016, 16(3): 298-306.
[11] Sallam M Y, El-Gowilly S M, Abdel-Galil A G A, et al. Central GABA A receptors are involved in inflammatory and cardiovascular consequences of endotoxemia in conscious rats[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389(3): 279-288.
[12] Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade[J]. Cytokine & Growth Factor Reviews, 2015, 26(5): 475-487.
[13] Suzuki S, Tanaka K, Suzuki N. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects[J]. Journal of Cerebral Blood Flow & Metabolism, 2009, 29(3): 464-479.
[14] Ali C, Nicole O, Docagne F, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitoxicity in the brain[J]. Journal of Cerebral Blood Flow & Metabolism, 2000, 20(6): 956-966.
[15] Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6[J]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2011, 1813(5): 878-888.
[15] Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions[J]. Clinical Science, 2012, 122(4): 143-159.
[16] Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition[J]. Current Opinion in Immunology, 2015, 34: 75-82.
[17] Habecker B A, Klein M G, Cox B C, et al. Norepinephrine transporter expression in cholinergic sympathetic neurons: differential regulation of membrane and vesicular transporters[J]. Developmental Biology, 2000, 220(1): 85-96.
[18] Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition[J]. Current Opinion in Immunology, 2015, 34: 75-82.
[19] Chen X, Wei J, Li C, et al. Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells[J]. International Journal of Oncology, 2018, 52(2): 571-578.
[20] Todd L, Squires N, Suarez L, et al. Jak/Stat signaling regulates the proliferation and neurogenic potential of Müller glia-derived progenitor cells in the avian retina[J]. Scientific Reports, 2016, 6: 35703.
[21] Gao H L, Yu X J, Liu K L, et al. PVN blockade of p44/42 MAPK pathway attenuates salt-induced hypertension through modulating neurotransmitters and attenuating oxidative stress[J]. Scientific Reports, 2017, 7: 43038.
[22] Oshima T, Cao X, Grande F, et al. Combination effects of SC144 and cytotoxic anticancer agents[J]. Anti-cancer Drugs, 2009, 20(5): 312-320.
[23] Xu S, Grande F, Garofalo A, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer[J]. Molecular Cancer Therapeutics, 2013.
[24] Plasencia C, Grande F, Oshima T, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity[J]. Cancer Biology & Therapy, 2009, 8(5): 458-465.
[25] Sung P H, Lee F Y, Lin L C, et al. Melatonin attenuated brain death tissue extract-induced cardiac damage by suppressing DAMP signaling[J]. Oncotarget, 2018, 9(3): 3531.
[26] Su Q, Huo C J, Li H B, et al. Renin-angiotensin system acting on reactive oxygen species in paraventricular nucleus induces sympathetic activation via AT1R/PKCγ/Rac1 pathway in salt-induced hypertension[J]. Scientific Reports, 2017, 7: 43107.
[27] Yin J, Wang Y, Hu H, et al. P2X7 receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL‐1β pathway[J]. Journal of Cellular and Molecular Medicine, 2017, 21(11): 2695-2710.
[28] Yin J, Hu H, Li X, et al. Inhibition of Notch signaling pathway attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats post-myocardial infarction[J]. American Journal of Physiology-Cell Physiology, 2015, 310(1): C41-C53.
[29] Martin D S, Haywood J R. Sympathetic nervous system activation by glutamate injections into the paraventricular nucleus[J]. Brain Research, 1992, 577(2): 261-267.
[30] Zhang K, Patel K P. Effect of nitric oxide within the paraventricular nucleus on renal sympathetic nerve discharge: role of GABA[J]. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1998, 275(3): R728-R734.
[31] Kang S, Tanaka T, Narazaki M, et al. Targeting interleukin-6 signaling in clinic[J]. Immunity, 2019, 50(4): 1007-1023.